<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Consilium Medicum</journal-id><journal-title-group><journal-title xml:lang="en">Consilium Medicum</journal-title><trans-title-group xml:lang="ru"><trans-title>Consilium Medicum</trans-title></trans-title-group><trans-title-group xml:lang="zh"><trans-title>Consilium Medicum</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2075-1753</issn><issn publication-format="electronic">2542-2170</issn><publisher><publisher-name xml:lang="en">Consilium Medicum</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">94047</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Lechenie erektil'noy disfunktsii: effekty‌‌ sildenafila</article-title><trans-title-group xml:lang="ru"><trans-title>Лечение эректильной дисфункции: эффекты‌‌ силденафила</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Vertkin</surname><given-names>A. L</given-names></name><name xml:lang="ru"><surname>Верткин</surname><given-names>А. Л</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Morgunov</surname><given-names>L. Yu</given-names></name><name xml:lang="ru"><surname>Моргунов</surname><given-names>Л. Ю</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en"></institution></aff><aff><institution xml:lang="ru">ГБОУ ВПО МГМСУ им. А.И.Евдокимова Минздрава России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2014-02-15" publication-format="electronic"><day>15</day><month>02</month><year>2014</year></pub-date><volume>16</volume><issue>2</issue><issue-title xml:lang="en">VOL 16, NO2 (2014)</issue-title><issue-title xml:lang="ru">ТОМ 16, №2 (2014)</issue-title><fpage>63</fpage><lpage>66</lpage><history><date date-type="received" iso-8601-date="2021-12-28"><day>28</day><month>12</month><year>2021</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2014, Consilium Medicum</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2014, ООО "Консилиум Медикум"</copyright-statement><copyright-year>2014</copyright-year><copyright-holder xml:lang="en">Consilium Medicum</copyright-holder><copyright-holder xml:lang="ru">ООО "Консилиум Медикум"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-sa/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://consilium.orscience.ru/2075-1753/article/view/94047">https://consilium.orscience.ru/2075-1753/article/view/94047</self-uri><abstract xml:lang="ru"><p>Исследования в области нейрофизиологии эрекции привели к существенному прогрессу в лечении больных с эректильной дисфункцией ЭД. Они увенчались созданием принципиально нового средства в лечении данного заболевания - ингибитора фосфодиэстеразы 5-го типа (ФДЭ-5) силденафила, отвечающего всем современным требованиям, предъявляемым к терапии ЭД. Этот препарат признан средством 1-й линии в лечении ЭД, он высокоэффективен и надежен, прост в употреблении, обладает малым числом побочных эффектов. На сегодня силденафил является «золотым стандартом» в лечении ЭД.</p></abstract><kwd-group xml:lang="ru"><kwd>эректильная дисфункция</kwd><kwd>лечение</kwd><kwd>силденафил</kwd><kwd>Торнетис</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Ayta I.A, Mc Kinlay J.B, Krane R.J. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int 1999; 84 (1): 50-6.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Wagner G, Fugl-Meyer K.S, Fugl-Meyer A.R. Impact of erectile dysfunction on quality of life: patient and partner perspectives. Int J Impot Res 2000; 4 (S1): 44-6.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Corona G, Mondaini N, Ungar A et al. Phosphodiesterase type 5 (PDE5) inhibitors in erectile dysfunction: the proper drug for the proper patient. J Sex Med 2011; 8 (12): 3418-32.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Gresser U, Gleiter C.H. Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil, and tadalafil review of the literature. Eur J Med Res 2002; 7: 435-46.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Mc Cullough A.R. Four - year review of sildenafil citrate. Rev Urol 2002; 4 (Suppl. 3): S26-38.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Carson C.C. Sildenafil: a 4-yearupdate in the treatment of 20 million erectile dysfunction patients. Curr Urol Rep 2003; 4 (6): 488-96.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Brown M, Prisant L.M, Collins M. Effect of sildenafil in patients with erectile dysfunction takin antihypertensive therapy. Am J Hematol 2001; 14: 70-3.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Sunwoo S, Kim Y.S, Cho B.L et al. Post - marketing surveillance study of the safety and efficacy of sildenafil prescribed in primary care to erectile dysfunction patients. Int J Impot Res. 2005; 17 (1): 71-5.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Rashid A. The efficacy and safety of PDE5 inhibitors. Clin Cornerstone 2005; 7 (1): 47-56.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Taylor J et al. Differences in side - effect duration and related bother levels between phosphodiesterase type 5 inhibitors. BJU Int 2009; 103: 1392-5.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Leslie S.J et al. No adverse hemodynamic interaction between sildenafil and red wine. Clin Pharmacol Ther 2004; 76: 365-70.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Kennedy S.H, Dugre H, Defoy I. A multicenter, double - blind, placebo - controlled study of sildenafil citrate in Canadian men with erectile dysfunction and untreated symptoms of depression, in the absence of major depressive disorder. Int Clin Psychopharmacol 2011; 26 (3): 151-8.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Dording C.M, La Rocca R.A, Hails K.A et al. The effect of sildenafil on quality of life. Ann Clin Psychiatry 2013; 25 (1): 3-10.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Abolyosr A, Elsagheer G.A, Abdel-Kader M.S et al. Evaluation of the effect of sildenafil and/or doxazosin on Benign prostatic hyperplasia - related lower urinary tract symptoms and erectile dysfunction. Urol Ann 2013; 5 (4): 237-40.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Cui H, Liu B, Song Z et al. Efficacy and safety of long - term tadalafil 5 mg once daily combined with sildenafil 50 mg as needed at the early stage of treatment for patients with erectile dysfunction. Andrologia 2014 Jan 6; doi: 10.1111/and.12216.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Spitzer M, Bhasin S, Travison T.G et al. Sildenafil increases serum testosterone levels by a direct action on the testes. Andrology 2013; 1 (6): 913-8.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Buvat J, Hatzichristou D, Maggi M et al. Efficacy, tolerability and satisfaction with sildenafil citrate 100-mg titration compared with continued 50-mg dose treatment in men with erectile dysfunction. BJU Int 2008; 102 (11): 1645-50.</mixed-citation></ref></ref-list></back></article>
